MARKAZIY NERV TIZIMINING BOLALARDA JAMOATDAN ORTTIRILGAN PNEVMONIYADAGI SHIKASTLANISHI
Abstrakt
Dolzarbligi. Nafas tizimi kasalliklaridan shifoxonadan tashqari pnevmoniya(ShTP) asoratlar bilan kechish xos bo‘lib bolalar orasida 20%gacha uchraydi. ShTP bilan og‘rigan bolalarda nafas yetishmovchiligidan tashqari, markaziy asab tizimida (MAT) aniqlanadigan asoratlar ham tez-tez kuzatilib turadi. Bu asoratlarga toksik – metabolik sindrom, talvasa sindromi, gipoksik ensefalopatiyalar kiradi. Tadqiqotning maqsadi. ShTPni bolalarda MAT va yurak zararlanishi bilan kechganda erta tashxislash, asoratlarni oldini olish va davolashni optimallashtirish. Tekshiruvlar va usullar. Toshkent tibbiyot akademiyasining ko‘p tarmoqli klinikasida davolangan 48 ShTP bilan kasallangan bola kuzatilgan, va 14(29,16%) bolalarda toksik – metabolik sindrom, 12(25,00%)da yurak qon – tomir tizimi tomonidan patologik o‘zgarishlar aniqlangan. Nafas yetishmovchiligi darajalari, 02 saturatsiyasi ko‘rsatkichlari aniqlangan, miyaning ultratovush tekshiruvi, EKG va umumiy klinik-laborator tekshiruvlar o‘tkazilgan. Tadqiqotning natijalari. Bemor bolalarning 15 (31,25%) nafarida ShTPning og‘ir kechishi aniqlangan III darajali Ne belgilari, saturatsiya ko‘rsatkichi ≤85,0%, bosh miyada UTTtekshiruvida 16,6% gipoksiya belgilari. Davolangan bemor bolalarning 14(29,16%)da asab tizimi shikastlanishi belgilari (injiqlik 18 (37,5%), uyquning buzilishi 17 (35,41%),, 12(25,00%)da yurak qon – tomir tizimi tomonidan patologik o‘zgarishlar aniqlangan (QRS kompleksining pasayishi15(31,25%), Giss tutamining o‘ng oyoqchasi 7( 14,58%) va chap oyoqchasi 4(8,33%) nafarida qisman blokadasi kuzatilgan. Xulosa. ShTP og‘ir kechishini, MAT va yurak shikastlanishini erta tashxislash va davolashni optimallashtirish uchun, Ne belgilarini, o‘pkaning rentgen, UTT, MSKT hamda EKGlarni o‘tkazish, 02 saturatsiyasini ko‘rsatkichini aniqlash va korreksiya qilish, bolalar nevropatologi va kardiologi maslaxatlarini olish kerak.
Mualliflar haqida
Adabiyotlar ro'yxati
Meyer Sauteur PM, Beeton ML, on behalf of the ESGMAC and the ESGMAC Mycoplasma pneumoniae Surveillance (MAPS) study group. Mycoplasma pneumoniae: delayed re-emergence after COVID-19 pan demic restrictions. Lancet Microbe. 2023;23:S2666-5247(2623)00344 00340. doi: 10.1016/S2666-5247(23)00344-0.
Youn YS, Lee KY. Mycoplasma pneumoniae pneumonia in children. Korean Journal of Pediatrics 2012; 55(2):42-7. ttps:doi:10.3345/kjp.2012.55.2.42
Karimdzhanov I.A., Madaminova M.Sh., Iskanova G.Kh., Gazieva A.S., Togaev M.Q. Diagnosis and treatment of community-acquired pneumonia in children. Child health, 2024, T.19, N5, 2024, p.65-68
Danino D, Ben-Shimol S, Van Der Beek BA, Givon-Lavi N, Avni YS, et al. Decline in pneumococcal disease in young children du ring the coronavirus disease 2019 (COVID-19) pandemic in Israel as sociated with suppression of seasonal respiratory viruses, despite persis tent pneumococcal carriage: a prospective cohort study. Clin Infect Dis. 2022;75:e1154-e1164. doi: 10.1093/cid/ciab1014
Karimdzhanov IA, Iskanova GKh, Isroilova NA. Sequential therapy of community-acquired pneumonia in children. Child’s Health. 2014;3(54):70-73. doi: 10.22141/2224-0551.3.54.2014.76003.
Bielicki JA, Stohr W, Barratt S, Dunn D, Naufal N, et al. Effect of amoxicillin dose and treatment duration on the need for antibiotic re-treatment in children with community-acquired pneumonia: the CAP-IT randomized clinical trial. JAMA. 2021;326:1713-1724. doi: 10.1001/jama.2021.17843.
Kuitunen I, Jaaskelainen J, Korppi M, Renko M. Antibiotic treatment duration for community-acquired pneumonia in outpatient children in high-income countries — a systematic review and meta-analysis. Clin Infect Dis. 2023;76:e1123-e1128. doi: 10.1093/cid/ciac374.
Furman E.G., Balkunova Yu.N., Boyko M.Yu., Estemesova R.A. Ultrasound examination of the lungs in the diagnosis of pneumonia in children. Doctor.Ru. 2024;23(6):58–63. DOI: 10.31550/1727-2378-2024-23-6-58-63
Huang W, Xu X, Zhao W, Cheng Q. Refractory Mycoplasma pneu moniae in Children: A Systematic Review and Meta-analysis of Labora tory Features and Predictors. J Immunol Res. 2022 Jun 26;2022:9227838. doi: 10.1155/2022/9227838.
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.